Verrica Pharmaceuticals
VRCA
43 hedge funds and large institutions have $28.5M invested in Verrica Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
13% more capital invested
Capital invested by funds: $25.3M → $28.5M (+$3.26M)
10% more funds holding
Funds holding: 39 → 43 (+4)
0.67% less ownership
Funds ownership: 27.81% → 27.14% (-0.67%)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
+$1.14M |
| 2 |
CC
Cannell Capital
Alta,
Wyoming
|
+$616K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$565K |
| 4 |
BlackRock
New York
|
+$223K |
| 5 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$87.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$810K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$743K |
| 3 |
AC
Armistice Capital
New York
|
-$573K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$528K |
| 5 |
Squarepoint
New York
|
-$398K |
VRCA Hedge Fund Activity: Q2 2026 in Review
43 of the 8,303 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2026, worth a combined $28.5M — up 13% from $25.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VRCA positions and 5 closed out — a net gain of 4 holders — while 7 added to existing stakes and 11 trimmed.
The largest buyer was Mariner, adding an estimated $1.14M. The largest seller was DAFNA Capital Management, cutting an estimated $810K.
- 43 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2026, up from 39 in Q1 2026.
- Funds reported $28.5M of Verrica Pharmaceuticals stock for Q2 2026, up 13% quarter-over-quarter.
- 9 funds opened new Verrica Pharmaceuticals positions in Q2 2026 and 5 closed out, a net change of +4 holders.
- The largest Verrica Pharmaceuticals buyer in Q2 2026 was Mariner, an estimated $1.14M added.
- The largest Verrica Pharmaceuticals seller in Q2 2026 was DAFNA Capital Management, an estimated $810K sold.
Based on aggregated 13F filings for Q2 2026.